Arcturus Therapeutics Holdings IncQ) expected to post a loss of 90 cents a share - Earnings Preview
Arcturus Therapeutics Holdings IncQ) is projected to report a loss of 90 cents per share and a 55% decline in quarterly revenue to $22.435 million for the period ending June 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $48.00, significantly above its last closing price of $12.21. Recent quarterly performances show a mix of beats and misses against estimates, with the latest earnings estimate unchanged over the past three months.
- Arcturus Therapeutics Holdings Inc (ARCT.OQ) (ARCT.O) is expected to show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
- The San Diego California-based company is expected to report a 55.0% decrease in revenue to $22.435 million from $49.86 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
- LSEG’s mean analyst estimate for Arcturus Therapeutics Holdings Inc is for a loss of 90 cents per share.
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 12 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Arcturus Therapeutics Holdings Inc is $48.00, about 74.6% above its last closing price of $12.21 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -1.26 -1.33 -0.52 Beat 60.9
Dec. 31 2025 -0.52 -0.55 -1.11 Missed -102.2
Sep. 30 2024 -1.23 -1.22 -0.26 Beat 78.6
Jun. 30 2024 -1.51 -1.60 -0.64 Beat 60
Mar. -1.21 -1.19 -1.00 Beat 15.9
31 2024
Dec. 31 2023 -0.60 -0.99 -0.32 Beat 67.7
Sep. 30 2023 -1.72 -1.69 -0.61 Beat 63.9
Jun. 30 2023 -0.18 -0.21 -1.98 Missed -839.5
This summary was machine generated August 1 at 20:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
